Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15608020 | 0.88 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367396 | 0.88 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL15607863 | 0.87 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL27610450 | 0.85 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367317 | 0.82 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367395 | 0.82 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL28807491 | 0.81 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL24728704 | 0.81 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367306 | 0.80 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL174157 | 0.79 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1PKMTAAR1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | L3MBTL1 2029/4885ALDH1A1 140/4885PKM 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.